Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammad Kagzi

Internal Medicine Gurnee, IL Medical Doctor

NPI 1659347409 CMS profile 74247

731 S Il Route 21, Unit 120, Gurnee, IL 60031

Open in the dashboard

General payments

$11,042

572 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammad Kagzi of Gurnee, IL is reported in the CMS Open Payments database as having received $11,042 across 572 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,123 93
2024 General $1,777 81
2023 General $1,853 90
2022 General $1,656 83
2021 General $1,598 104
2020 General $816 52
2019 General $1,218 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammad Kagzi
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mohammad Kagzi were reported at $2,123. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mohammad Kagzi Internal Medicine median Middle half National median
2019 $1,218 $159 $48–$570 $163
2020 $816 $119 $33–$402 $114
2021 $1,598 $135 $37–$521 $132
2022 $1,656 $141 $42–$496 $149
2023 $1,853 $149 $45–$519 $160
2024 $1,777 $154 $47–$537 $164
2025 $2,123 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Harmony Biosciences LLC $2,210 99 payments
  2. Novo Nordisk Inc $1,223 73 payments
  3. AstraZeneca Pharmaceuticals LP $1,073 53 payments
  4. Jazz Pharmaceuticals Inc. $986 57 payments
  5. Lilly USA, LLC $866 49 payments
  6. GlaxoSmithKline, LLC. $720 42 payments
  7. AbbVie, Inc. $693 36 payments
  8. Inspire Medical Systems, Inc. $625 21 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $609 30 payments
  10. Vanda Pharmaceuticals Inc. $268 17 payments
  11. Other $1,769 95 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,651 566 payments
  2. Education $391 6 payments
Products named General payments · program years 2019–2025
  1. Wakix Neurological Disorders $706 38 payments
  2. Ozempic $640 34 payments
  3. INSPIRE $625 21 payments
  4. WAKIX Sleep Medicine $590 27 payments
  5. MOUNJARO $573 33 payments
  6. XYWAV $504 40 payments
  7. RYBELSUS $498 27 payments
  8. TRELEGY ELLIPTA $490 31 payments
  9. WAKIX Narcolepsy $483 23 payments
  10. UBRELVY $454 23 payments
  11. Other $7,447 379 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

1,240

Median for Internal Medicine: 777

Drug cost

$158,259

Median for Internal Medicine: $73,373

Branded share of claims

17.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 41 $48,712
Nucala Mepolizumab Brand 12 $42,787
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $22,671
Tradjenta Linagliptin Brand 13 $14,822
Myrbetriq Mirabegron Brand 11 $8,085
Bupropion Xl Bupropion Hcl Brand 16 $3,466
Ezetimibe Generic 23 $1,797
Nebivolol Hcl Generic 18 $1,123
Tacrolimus Generic 11 $998
Rosuvastatin Calcium Generic 59 $881

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$200,650

Medicare's payments for the services billed

Medicare patients

430

Average age 74

Services billed

2,975

186 women, 244 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 57%
Arthritis 50%
Diabetes 46%
Chronic kidney disease 30%
Atrial fibrillation 29%
Heart failure 27%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
$352 — —
MOUNJARO
$199 — —
AIRSUPRA
$176 — —
JARDIANCE
$100 — —
FARXIGA
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

572 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record